| Id: | acc3586 |
| Group: | 1sens |
| Protein: | STAT3 |
| Gene Symbol: | Stat3 |
| Protein Id: | P42227 |
| Protein Name: | STAT3_MOUSE |
| PTM: | phosphorylation |
| Site: | Tyr705 |
| Site Sequence: | EADPGSAAPYLKTKFICVTPT |
| Disease Category: | Digestive system diseases |
| Disease: | Hepatic Injury |
| Disease Subtype: | Fulminant hepatic failure |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | IL-22 |
| Drug Info: | IL - 22 is a cytokine that plays important roles in immune regulation and mucosal tissue protection. It is involved in various physiological and pathological processes. |
| Relation: |
IL-22
➜
STAT3-Tyr705
UP
➜
Hepatic Injury
Alleviate
|
| Effect: | modulate |
| Effect Info: | "IL-22 treatment significantly enhances the activation of STAT3 and upregulates the expression of Bcl-xL, heme oxygenase-1 (HO-1), and redox factor-1 (Ref-1) in GalN/LPS-induced liver injury. Overall, these data indicate that IL-22 can provide crucial protection against GalN/LPS-induced liver injury through anti-apoptotic, antioxidant, and anti-inflammatory effects." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 21843953 |
| Sentence Index: | 21843953_3 |
| Sentence: | "Administration of recombinant human IL-22 (rhIL-22) reduced the death rate markedly and prevented mice from severe hepatic injury, as evidenced by decreased serum alanine aminotransferase (ALT) and total bilirubin (T.Bil) activity as well as improved histological signs in liver." |
Sequence & Structure:
MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMDLTSECATSPM
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 705 | U | Neurofibromatosis | Phosphorylation | 23318430 |
| Y | 705 | U | Squamous cell carcinoma | Phosphorylation | 19934324 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
